Screener
Climb Bio, Inc. CLYM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $9,373 | $17,327 |
| General and administrative | 5,838 | 5,691 |
| Total operating expenses | 15,211 | 23,018 |
| Loss from operations | (15,211) | (23,018) |
| Other income (expense): | ||
| Interest income | 1,514 | 2,287 |
| Foreign currency (loss) | (25) | (50) |
| Total other income, net | 1,489 | 2,237 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s operating income?
- Climb Bio, Inc. (CLYM) reported operating income of -$15.21M in Q1 2026.
- How has Climb Bio, Inc.'s operating income changed year-over-year?
- Climb Bio, Inc.'s operating income increased by 33.9% year-over-year, from -$23.02M to -$15.21M.
- What is the long-term trend for Climb Bio, Inc.'s operating income?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s operating income has grown at a 17.5% compound annual growth rate (CAGR), from -$35.67M to -$67.88M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Climb Bio, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude